Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin versus dapagliflozin add-on to metformin with or without sulfonylurea in adults with type 2 diabetes mellitus and mild renal impairment
2014-005525-13Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin add-on arm with Dapagliflozin add-on arm (2 arms). Primary endpoint: Change from baseline in glycated hemoglobin. Started Aug 2015; status: completed.
02
Drugs
sitagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-005525-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005525-13.